Supernus Pharmaceuticals, Inc. SUPN
We take great care to ensure that the data presented and summarized in this overview for SUPERNUS PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SUPN
View all-
Black Rock Inc. New York, NY10.4MShares$369 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$218 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$181 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$102 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$93.5 Million0.09% of portfolio
-
State Street Corp Boston, MA2.16MShares$76.6 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X01.94MShares$68.9 Million0.37% of portfolio
-
Stephens Investment Management Group LLC1.93MShares$68.7 Million0.85% of portfolio
-
Pacer Advisors, Inc. Malvern, PA1.75MShares$62.3 Million0.13% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.73MShares$61.4 Million0.09% of portfolio
Latest Institutional Activity in SUPN
Top Purchases
Top Sells
About SUPN
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Insider Transactions at SUPN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 11
2024
|
Charles W Newhall Iii Director |
SELL
Open market or private sale
|
Direct |
10,700
-7.59%
|
$385,200
$36.24 P/Share
|
Nov 11
2024
|
Charles W Newhall Iii Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+12.42%
|
$180,000
$9.13 P/Share
|
Nov 08
2024
|
Frederick M. Hudson Director |
SELL
Open market or private sale
|
Direct |
8,722
-23.5%
|
$313,992
$36.28 P/Share
|
Nov 08
2024
|
Jack A. Khattar President, CEO |
SELL
Open market or private sale
|
Direct |
125,000
-11.89%
|
$4,500,000
$36.29 P/Share
|
Nov 08
2024
|
Jack A. Khattar President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
125,000
+10.63%
|
$1,125,000
$9.13 P/Share
|
Nov 08
2024
|
Georges Gemayel Director |
SELL
Open market or private sale
|
Direct |
10,787
-44.76%
|
$388,332
$36.3 P/Share
|
Nov 08
2024
|
Georges Gemayel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,787
+30.92%
|
$118,657
$11.46 P/Share
|
Nov 07
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Open market or private sale
|
Direct |
15,000
-64.66%
|
$540,000
$36.98 P/Share
|
Nov 07
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+39.27%
|
$135,000
$9.13 P/Share
|
Nov 07
2024
|
Jack A. Khattar President, CEO |
SELL
Open market or private sale
|
Direct |
125,000
-11.89%
|
$4,500,000
$36.68 P/Share
|
Nov 07
2024
|
Jack A. Khattar President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
125,000
+10.63%
|
$1,125,000
$9.13 P/Share
|
Nov 07
2024
|
Georges Gemayel Director |
SELL
Open market or private sale
|
Direct |
14,213
-51.63%
|
$511,668
$36.62 P/Share
|
Nov 07
2024
|
Georges Gemayel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,213
+34.05%
|
$156,343
$11.46 P/Share
|
Sep 13
2024
|
Georges Gemayel Director |
SELL
Open market or private sale
|
Direct |
13,886
-32.74%
|
$430,466
$31.33 P/Share
|
Sep 13
2024
|
Georges Gemayel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+30.02%
|
$110,000
$11.46 P/Share
|
Sep 03
2024
|
Jack A. Khattar President, CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,045
-1.07%
|
$341,530
$34.9 P/Share
|
Sep 03
2024
|
Jack A. Khattar President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,000
+2.19%
|
-
|
Aug 20
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
572
-5.58%
|
$16,588
$29.57 P/Share
|
Aug 20
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+10.87%
|
-
|
Mar 21
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
14,491
-62.84%
|
$507,185
$35.31 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 31.1K shares |
---|---|
Exercise of conversion of derivative security | 527K shares |
Other acquisition or disposition | 16.5K shares |
Payment of exercise price or tax liability | 45.2K shares |
---|---|
Open market or private sale | 443K shares |
Other acquisition or disposition | 16.5K shares |